Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Alphyn Capital Management Samer Hakoura | “Fairfax's progress over the last three years has been a textbook exercise in compounding. Hard-market pricing from 2022 to 2024 enabled the group to expand net written premiums at a double-digit clip, increasing float to $33 billion, up roughly 12% per year since 2020. With that larger float invested in longer-duration bonds, interest and dividend income have climbed from $0.6 billion in 2021 to about $2.5 billion last year. Adding a steady $1bn+ of associate earnings and normalized underwriting profit, Fairfax is positioned to earn more than $165 per share in 2025, over triple the approximately $52 per-share run rate we underwrote in 2019. These four pillars, disciplined underwriting, growing float, higher fixed-income yields, and associate contributions, have driven the company's outperformance since 2022. The share price has adjusted accordingly: Fairfax now trades at around 1.7x stated book value, or 1.5x forward, rewarding us with both earnings growth and multiple expansion. The insurance hard market may be coming to an end, and even if premium growth slows to the 6% base-case forecast and the combined ratio drifts toward the high 90s, management still expects more than $1.5 billion in underwriting profit, in addition to the recurring income streams noted above. A substantial cash cushion and excess capital across the underwriting subsidiaries provide Fairfax with flexibility to continue repurchasing shares or reinvest opportunistically. While we should not expect the same pace of multiple expansion from here, the company's scalable earnings engine and conservative balance sheet leave ample room for attractive, though more measured, long-term returns. BSD Analysis: Fairfax is the anti-flash insurer — boring on the surface, lethal in capital allocation under the hood. Underwriting discipline has tightened dramatically, investment returns are improving in a higher-rate world, and Fairfax is quietly compounding book value at a clip that would make most insurers jealous. Watsa's value investing style is finally back in favor as credit markets normalize. The market still prices Fairfax like the messy 2010s version — not today's leaner, more profitable compounder.” | BULL | Q2 2025 Jul 1, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
